260 related articles for article (PubMed ID: 10232150)
1. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
2. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
4. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
5. Future directions in non-small cell lung cancer.
Schiller JH
Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
[TBL] [Abstract][Full Text] [Related]
6. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
7. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
8. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
[TBL] [Abstract][Full Text] [Related]
9. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
10. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
12. Amifostine and combined-modality therapeutic approaches.
Mehta MP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomics of amifostine in ovarian cancer.
Calhoun EA; Bennett CL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
[TBL] [Abstract][Full Text] [Related]
14. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
15. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
16. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
17. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
18. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
[TBL] [Abstract][Full Text] [Related]
19. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
20. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?
Komaki R
J Clin Oncol; 2005 Oct; 23(28):7232-3; author reply 7233-5. PubMed ID: 16192612
[No Abstract] [Full Text] [Related]
[Next] [New Search]